JP2016515098A5 - - Google Patents

Download PDF

Info

Publication number
JP2016515098A5
JP2016515098A5 JP2015560285A JP2015560285A JP2016515098A5 JP 2016515098 A5 JP2016515098 A5 JP 2016515098A5 JP 2015560285 A JP2015560285 A JP 2015560285A JP 2015560285 A JP2015560285 A JP 2015560285A JP 2016515098 A5 JP2016515098 A5 JP 2016515098A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
dimethyl
carbazole
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015560285A
Other languages
English (en)
Japanese (ja)
Other versions
JP6395731B2 (ja
JP2016515098A (ja
Filing date
Publication date
Priority claimed from US14/190,477 external-priority patent/US9492460B2/en
Application filed filed Critical
Publication of JP2016515098A publication Critical patent/JP2016515098A/ja
Publication of JP2016515098A5 publication Critical patent/JP2016515098A5/ja
Application granted granted Critical
Publication of JP6395731B2 publication Critical patent/JP6395731B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015560285A 2013-02-27 2014-02-27 ブロモドメイン阻害剤として有用なカルバゾール化合物 Active JP6395731B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361769996P 2013-02-27 2013-02-27
US61/769,996 2013-02-27
US14/190,477 2014-02-26
US14/190,477 US9492460B2 (en) 2013-02-27 2014-02-26 Carbazole compounds useful as bromodomain inhibitors
PCT/US2014/018820 WO2014134232A1 (en) 2013-02-27 2014-02-27 Carbazole compounds useful as bromodomain inhibitors

Publications (3)

Publication Number Publication Date
JP2016515098A JP2016515098A (ja) 2016-05-26
JP2016515098A5 true JP2016515098A5 (enExample) 2017-03-30
JP6395731B2 JP6395731B2 (ja) 2018-09-26

Family

ID=50382555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015560285A Active JP6395731B2 (ja) 2013-02-27 2014-02-27 ブロモドメイン阻害剤として有用なカルバゾール化合物

Country Status (10)

Country Link
US (1) US9492460B2 (enExample)
EP (1) EP2961748B1 (enExample)
JP (1) JP6395731B2 (enExample)
CN (1) CN105008352B (enExample)
BR (1) BR112015020389A8 (enExample)
CA (1) CA2902737A1 (enExample)
EA (1) EA027345B1 (enExample)
ES (1) ES2669189T3 (enExample)
MX (1) MX2015010921A (enExample)
WO (1) WO2014134232A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2666530C2 (ru) 2012-01-12 2018-09-11 Йейл Юниверсити Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014096965A2 (en) 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Novel heterocyclic compounds as bromodomain inhibitors
JP6404838B2 (ja) 2013-02-27 2018-10-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ブロモドメイン阻害剤として有用なカルバゾール化合物
EP2970312B1 (en) 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
WO2015004533A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
SG11201510409QA (en) 2013-06-21 2016-01-28 Zenith Epigenetics Corp Novel bicyclic bromodomain inhibitors
WO2015006193A1 (en) 2013-07-08 2015-01-15 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
WO2015015318A2 (en) 2013-07-31 2015-02-05 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
DK3466949T3 (da) * 2013-12-24 2021-03-15 Bristol Myers Squibb Co Tricyklisk forbindelse som anticancermidler
US9580430B2 (en) 2014-02-28 2017-02-28 The Regents Of The University Of Michigan 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
UA119870C2 (uk) 2014-04-23 2019-08-27 Інсайт Корпорейшн 1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET
MX2016014574A (es) * 2014-05-08 2017-02-23 Oncoethix Gmbh El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo.
ES2855225T3 (es) 2014-09-15 2021-09-23 Incyte Corp Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
BR112017006342A2 (pt) * 2014-10-02 2017-12-19 Glaxosmithkline Ip No 2 Ltd composto de sal de ácido benzenossulfônico, forma em estado sólido cristalino, composição farmacêutica, produto farmacêutico de combinação, método de tratamento de doenças ou condições, uso de um composto de sal de ácido benzenossulfônico, e, processo para preparação de um composto de sal de ácido benzenossulfônico.
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
EP3227280B1 (en) 2014-12-01 2019-04-24 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
JP2017537946A (ja) 2014-12-11 2017-12-21 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての置換複素環
HK1245247A1 (zh) 2014-12-17 2018-08-24 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
AU2016232705C1 (en) 2015-03-18 2021-06-17 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2016183114A1 (en) * 2015-05-11 2016-11-17 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
ES2770349T3 (es) 2015-05-12 2020-07-01 Bristol Myers Squibb Co Compuestos de 5H-pirido[3,2-b]indol como agentes antineoplásicos
US9725449B2 (en) * 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
JP2018526430A (ja) 2015-07-10 2018-09-13 アルヴィナス・インコーポレイテッド タンパク質分解のｍｄｍ２系修飾因子および関連の使用方法
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
WO2017165139A1 (en) 2016-03-25 2017-09-28 St. Jude Children's Research Hospital 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane x receptor
WO2017172914A1 (en) 2016-03-30 2017-10-05 Wisconsin Alumni Research Foundation Methods and compositions for modulating frataxin expression
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
AU2017281286B2 (en) 2016-06-20 2021-05-20 Incyte Corporation Crystalline solid forms of a bet inhibitor
JP2020506922A (ja) 2017-01-31 2020-03-05 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物
WO2018183679A1 (en) 2017-03-29 2018-10-04 Wisconsin Alumni Research Foundation Methods and compositions for modulating gene expression
WO2019148055A1 (en) 2018-01-26 2019-08-01 Yale University Imide-based modulators of proteolysis and methods of use
PE20221582A1 (es) 2019-12-19 2022-10-06 Arvinas Operations Inc Compuestos y metodos para la degradacion dirigida de receptor de androgenos
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN111809182B (zh) * 2020-07-08 2025-04-18 江苏和达电子科技有限公司 一种用于铜/钼（铌）/igzo膜层的刻蚀液及其制备方法和应用
US12016847B2 (en) 2021-03-12 2024-06-25 Bristol-Myers Squibb Company Methods of treating prostate cancer
CA3255952A1 (en) * 2022-05-20 2023-11-23 University Of Puerto Rico 1,2,3-Triazoles 1,4,5-Trisubstitutes and their uses
WO2025049555A1 (en) 2023-08-31 2025-03-06 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
US12516051B1 (en) 2024-09-30 2026-01-06 St. Jude Children's Research Hospital, Inc. Small molecule degraders and fluorescent probes of PXR

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310635D0 (en) * 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds
US6177440B1 (en) 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
WO2002000255A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for cancer
ATE353876T1 (de) * 2001-03-28 2007-03-15 Lilly Co Eli Substituierte carbazole als inhibitoren von spla2
US6602619B2 (en) 2001-10-19 2003-08-05 Lightronik Technology Inc. Organic EL device
WO2005039569A1 (en) 2003-10-18 2005-05-06 Bayer Healthcare Ag 5-substituted 2-(phenylmethyl) thio-4-phenyl-4h-1,2,4-triazole derivatives and related compounds as gaba-agonists for the treatment of urinary incontinence and related diseases
WO2006012310A2 (en) * 2004-06-25 2006-02-02 Genzyme Corporation Carbazole derivatives for treating polycystic kidney disease
CN102325752B (zh) * 2008-12-19 2015-02-04 百时美施贵宝公司 咔唑和咔啉激酶抑制剂
MY160456A (en) * 2009-11-05 2017-03-15 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
EP2566858A2 (en) 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
JP5623996B2 (ja) 2010-09-21 2014-11-12 株式会社半導体エネルギー研究所 カルバゾール誘導体
JP5842630B2 (ja) 2011-03-16 2016-01-13 株式会社リコー カルバゾール誘導体、及び半導体ナノ結晶
EP2694619A4 (en) * 2011-05-03 2014-10-22 Rohm & Haas Elect Mat NEW ORGANIC ELECTROLUMINESCENSE COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE THEREWITH
UA115576C2 (uk) * 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4

Similar Documents

Publication Publication Date Title
JP2016515098A5 (enExample)
JP7654071B2 (ja) 複素環スピロ化合物及び使用方法
TWI579284B (zh) 咪唑并吡咯啶酮化合物
AU2008236562B2 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha
JP2025508702A (ja) キナゾリン化合物、及び変異ｋｒａｓタンパク質の阻害剤としてのその使用
JP2024517695A (ja) 複素環式化合物及び使用方法
RU2665036C2 (ru) Гетероароматические соединения-модуляторы фосфоинозидит-3-киназы и способы применения
JP6935415B2 (ja) ２−アミノ−Ｎ−［７−メトキシ−２，３−ジヒドロイミダゾ−［１，２−ｃ］キナゾリン−５−イル］ピリミジン−５−カルボキサミド類
RU2672910C9 (ru) Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы
WO2016203404A1 (en) Compounds and compositions for inhibiting the activity of shp2
JP2017524702A5 (enExample)
WO2019071147A1 (en) INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
JP2016537384A5 (enExample)
JP2016530283A5 (enExample)
JP2012532131A5 (enExample)
JP2016523974A5 (enExample)
JP2023549055A (ja) 複素環式スピロ化合物及びその使用方法
JP2014518544A5 (enExample)
RU2014152790A (ru) Пирролопиразоновые ингибиторы танкиразы
WO2016151499A1 (en) Formylated n-heterocyclic derivatives as fgfr4 inhibitors
JP2016509056A5 (enExample)
RU2014126750A (ru) Ингибиторы тирозинкиназы брутона
RU2019108717A (ru) Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов
FI3478284T3 (fi) Yhdisteitä ja koostumuksia syövän hoitoon
WO2016193955A1 (en) Combinations of kinase inhibitors for treating colorectal cancer